| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
138,140,000 |
| Market
Cap: |
142.28(M) |
| Last
Volume: |
3,241,097 |
Avg
Vol: |
3,286,692 |
| 52
Week Range: |
$0.92 - $1.31 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
| |
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 807 |
| Guru Rank Value : 1 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Spectrum Pharmaceuticals is a biopharmaceutical company. Co. is engaged in acquiring, developing, and commercializing targeted oncology therapies. Co. has two drugs in late-stage development: Eflapegrastim, which is a long-acting granulocyte colony-stimulating factor for the treatment of chemotherapy-induced neutropenia; as well as Poziotinib, which is an irreversible tyrosine kinase inhibitor under investigation for non-small cell lung cancer tumors with various mutations.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
50,000 |
| Total Buy Value |
$0 |
$0 |
$0 |
$22,500 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
0 |
0 |
32,387 |
490,738 |
| Total Sell Value |
$0 |
$0 |
$35,496 |
$343,474 |
| Total People Sold |
0 |
0 |
1 |
7 |
| Total Sell Transactions |
0 |
0 |
1 |
19 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Mcgahan Keith M |
Chief Legal Officer |
• – – |
2020-08-12 |
4 |
AS |
$3.71 |
$928 |
D/D |
(250) |
248,769 |
|
5% |
|
| Mcgahan Keith M |
Chief Legal Officer |
• – – |
2020-08-11 |
4 |
AS |
$4.03 |
$1,183 |
D/D |
(294) |
249,019 |
|
15% |
|
| Mcgahan Keith M |
Chief Legal Officer |
• – – |
2020-07-09 |
4 |
AS |
$3.36 |
$46,640 |
D/D |
(13,881) |
249,313 |
|
24% |
|
| Mcgahan Keith M |
Chief Legal Officer |
• – – |
2020-06-24 |
4 |
AS |
$3.21 |
$50,631 |
D/D |
(15,773) |
262,986 |
|
19% |
|
| Lebel Francois |
Chief Medical Officer |
• – – |
2020-06-23 |
4 |
AS |
$3.35 |
$13,959 |
D/D |
(4,167) |
292,729 |
|
9% |
|
| Ashton William |
Director |
– • – |
2020-06-22 |
4 |
AS |
$3.25 |
$16,250 |
D/D |
(5,000) |
41,666 |
|
5% |
|
| Lebel Francois |
Chief Medical Officer |
• – – |
2020-06-22 |
4 |
AS |
$3.16 |
$17,320 |
D/D |
(5,474) |
296,896 |
|
5% |
|
| Mcgahan Keith M |
Chief Legal Officer |
• – – |
2020-06-22 |
4 |
AS |
$3.25 |
$9,750 |
D/D |
(3,000) |
278,759 |
|
5% |
|
| Mcgahan Keith M |
Chief Legal Officer |
• – – |
2020-06-19 |
4 |
AS |
$3.13 |
$10,820 |
D/D |
(3,459) |
281,759 |
|
6% |
|
| Czerepak Elizabeth |
Director |
– • – |
2020-06-18 |
4 |
A |
$0.00 |
$0 |
D/D |
30,000 |
40,000 |
|
- |
|
| Ashton William |
Director |
– • – |
2020-06-18 |
4 |
A |
$0.00 |
$0 |
D/D |
30,000 |
46,666 |
|
- |
|
| Vyas Dolatrai |
Director |
– • – |
2020-06-18 |
4 |
A |
$0.00 |
$0 |
D/D |
30,000 |
81,069 |
|
- |
|
| Fischer Seth H.z. |
Director |
– • – |
2020-06-18 |
4 |
A |
$0.00 |
$0 |
D/D |
30,000 |
32,500 |
|
- |
|
| Vacirca Jeff L |
Director |
– • – |
2020-06-18 |
4 |
A |
$0.00 |
$0 |
D/D |
30,000 |
66,967 |
|
- |
|
| Welles Bernice R |
Director |
– • – |
2020-06-18 |
4 |
A |
$0.00 |
$0 |
D/D |
30,000 |
50,000 |
|
- |
|
| Vacirca Jeff L |
Director |
– • – |
2020-05-15 |
4 |
A |
$3.11 |
$15,550 |
D/D |
5,000 |
36,967 |
|
- |
|
| Riga Thomas J |
EVP, COO & CCO |
• – – |
2020-05-14 |
4 |
AS |
$3.06 |
$3,443 |
D/D |
(1,125) |
416,433 |
|
36% |
|
| Mcgahan Keith M |
Chief Legal Officer |
• – – |
2020-05-14 |
4 |
AS |
$3.06 |
$1,071 |
D/D |
(350) |
285,218 |
|
36% |
|
| Riga Thomas J |
EVP, COO & CCO |
• – – |
2020-05-13 |
4 |
AS |
$3.25 |
$6,769 |
D/D |
(2,086) |
417,558 |
|
42% |
|
| Mcgahan Keith M |
Chief Legal Officer |
• – – |
2020-05-13 |
4 |
AS |
$3.25 |
$1,298 |
D/D |
(400) |
285,568 |
|
42% |
|
| Fischer Seth H.z. |
Director |
– • – |
2020-04-23 |
4 |
A |
$0.00 |
$0 |
D/D |
2,500 |
2,500 |
|
- |
|
| Lebel Francois |
Chief Medical Officer |
• – – |
2020-04-03 |
4 |
AS |
$2.18 |
$1,862 |
D/D |
(854) |
302,370 |
|
70% |
|
| Lebel Francois |
Chief Medical Officer |
• – – |
2020-04-02 |
4 |
AS |
$2.17 |
$2,667 |
D/D |
(1,228) |
303,224 |
|
66% |
|
| Turgeon Joseph W. |
CEO & President |
• • – |
2020-04-01 |
4 |
AS |
$2.23 |
$5,579 |
D/D |
(2,502) |
691,134 |
|
49% |
|
| Riga Thomas J |
EVP, COO & CCO |
• – – |
2020-04-01 |
4 |
AS |
$2.23 |
$2,092 |
D/D |
(938) |
419,644 |
|
49% |
|
658 Records found
|
|
Page 6 of 27 |
|
|
